

1 **Title:** Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States
2 Veterans Aged 54-75 Years

3
4 **Authors:** Christopher T. Rentsch, Ph.D.^{1,2}, Farah Kidwai-Khan, MS^{1,3*}, Janet P. Tate, Sc.D.^{1,3*},
5 Lesley S. Park, Ph.D.^{4*}, Joseph T. King, Jr., M.D.^{1,5*}, Melissa Skanderson, MSW^{1*}, Ronald G.
6 Hauser, M.D.^{1,6}, Anna Schultze, Ph.D.², Christopher I. Jarvis, Ph.D.², Mark Holodniy, M.D.^{7,8},
7 Vincent Lo Re III, M.D.⁹, Kathleen M. Akgün, M.D.^{1,3}, Kristina Crothers, M.D.¹⁰, Tamar H. Taddei,
8 M.D.^{1,3}, Matthew S. Freiberg, M.D.^{11,12}, and Amy C. Justice, M.D.^{1,3,13}

- 9
10 1. VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven, CT,
11 US, 06516
12 2. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical
13 Medicine, London, UK, WC1E 7HT
14 3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, US, 06520
15 4. Stanford Center for Population Health Sciences, Stanford University School of Medicine,
16 Stanford, CA, US, 94305
17 5. Department of Neurosurgery, Yale School of Medicine, New Haven, CT, US, 06520
18 6. Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, US,
19 06520
20 7. VA Palo Alto Healthcare System, US Department of Veterans Affairs, Palo Alto, CA, US,
21 94304
22 8. Division of Infectious Diseases and Geographic Medicine, Stanford University School of
23 Medicine, Stanford, CA, US, 94305
24 9. Division of Infectious Diseases, Department of Medicine and Center for Clinical
25 Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and
26 Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,
27 US, 19104
28 10. VA Puget Sound Health Care System and Department of Medicine, University of
29 Washington School of Medicine, Seattle, WA, US, 98104
30 11. Geriatric Research Education and Clinical Center (GRECC), US Department of Veterans
31 Affairs, Tennessee Valley Health Care System, Nashville, TN, US 37212
32 12. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, US, 37232
33 13. Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven,
34 CT, US, 06511

35
36 *These authors contributed equally

37
38 **Sources of support:** This work was supported by National Institute on Alcohol Abuse and
39 Alcoholism [U01-AA026224, U24-AA020794, U01-AA020790, U10-AA013566].

40
41 **Conflicts of interest:** The authors declare no conflicts of interest.

42
43 **Words:** 2739

44 **Tables/Figures:** 4/1

45 **Key Points**

46 **Question:** What are the demographic and clinical characteristics associated with testing
47 positive for coronavirus 2019 (Covid-19+), and among Covid-19+ subsequent hospitalization
48 and intensive care among Veterans in the United States?

49 **Findings:** In this retrospective cohort study of 2,026,227 Veterans aged 54-75 years and active
50 in care, 585/3,789 (15.4%) tested Covid-19+. Black race was strongly associated with Covid-19+,
51 but not with hospitalization or intensive care. Among Covid-19+, laboratory abnormalities and a
52 summary measure of physiologic injury were strongly associated with hospitalization and
53 intensive care.

54 **Meaning:** Racial differences in testing positive for Covid-19 may be an underestimate of the
55 general population as racial health disparities in the Veterans Affairs Healthcare System tend to
56 be smaller than in the private sector. Risk of hospitalization and intensive care may be better
57 characterized by laboratory measures and vital signs than by comorbid conditions or prior
58 medication exposure.

59 **Abstract**

60 **Importance:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes
61 coronavirus disease 2019 (Covid-19), an evolving pandemic. Limited data are available
62 characterizing SARS-Cov-2 infection in the United States.

63 **Objective:** To determine associations between demographic and clinical factors and testing
64 positive for coronavirus 2019 (Covid-19+), and among Covid-19+ subsequent hospitalization
65 and intensive care.

66 **Design, Setting, and Participants:** Retrospective cohort study including all patients tested for
67 Covid-19 between February 8 and March 30, 2020, inclusive. We extracted electronic health
68 record data from the national Veterans Affairs Healthcare System, the largest integrated
69 healthcare system in the United States, on 2,026,227 patients born between 1945 and 1965
70 and active in care.

71 **Exposures:** Demographic data, comorbidities, medication history, substance use, vital signs, and
72 laboratory measures. Laboratory tests were analyzed first individually and then grouped into a
73 validated summary measure of physiologic injury (VACS Index).

74 **Main Outcomes and Measures:** We evaluated which factors were associated with Covid-19+
75 among all who tested. Among Covid-19+ we identified factors associated with hospitalization or
76 intensive care. We identified independent associations using multivariable and conditional
77 multivariable logistic regression with multiple imputation of missing values.

78 **Results:** Among Veterans aged 54-75 years, 585/3,789 (15.4%) tested Covid-19+. In adjusted
79 analysis (C -statistic=0.806) black race was associated with Covid-19+ (OR 4.68, 95% CI 3.79-
80 5.78) and the association remained in analyses conditional on site (OR 2.56, 95% CI 1.89-3.46).

81 In adjusted models, laboratory abnormalities (especially fibrosis-4 score [FIB-4] >3.25 OR 8.73,
82 95% CI 4.11-18.56), and VACS Index (per 5-point increase OR 1.62, 95% CI 1.43-1.84) were
83 strongly associated with hospitalization. Associations were similar for intensive care. Although
84 significant in unadjusted analyses, associations with comorbid conditions and medications were
85 substantially reduced and, in most cases, no longer significant after adjustment.

86 **Conclusions and Relevance:** Black race was strongly associated with Covid-19+, but not with
87 hospitalization or intensive care. Among Covid-19+, risk of hospitalization and intensive care
88 may be better characterized by laboratory measures and vital signs than by comorbid
89 conditions or prior medication exposure.

90 Introduction

91 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus
92 disease 2019 (Covid-19) and is an evolving pandemic. Limited data are available characterizing
93 SARS-Cov-2 infection in the United States. Unadjusted analyses restricted to Covid-19 cases in
94 China,¹⁻⁵ Italy,⁶ and the United States^{7,8} suggest that older age, diabetes, chronic obstructive
95 lung disease (COPD), hypertension, vascular disease, renal disease, and liver disease are
96 associated with more severe disease. Further, while some have speculated that use of
97 angiotensin converting enzyme inhibitor (ACE), angiotensin II receptor blockers (ARB), and
98 nonsteroidal anti-inflammatory drugs (NSAID) may exacerbate disease,^{9,10} no analysis of this
99 question has been published.

100

101 The Department of Veterans Affairs (VA) is the largest integrated healthcare system in the
102 United States. All care is recorded in a national electronic health record with daily uploads into
103 a central data repository. As a result, it is possible to extract data on patients tested for Covid-
104 19, including outpatient and inpatient records, laboratory values, and pharmacy fill/refill data.
105 When a well-characterized longitudinal cohort is supplemented with Covid-19 testing data, it is
106 possible to answer important questions rapidly using validated methods.

107

108 The VA Birth Cohort includes all Veterans born between 1945 and 1965, over 2 million living
109 individuals aged 54-75 years,^{11,12} a demographic at particularly high risk of adverse outcomes
110 from Covid-19.¹⁻⁴ Using unadjusted and adjusted analyses, we consider a wide range of factors

111 either associated with testing positive for Covid-19 and subsequent hospitalization and
112 intensive care in the national VA system as of March 30, 2020.

113

114 **Methods**

115 *Data Source*

116 Using data from the VA national Corporate Data Warehouse on members of the VA Birth
117 Cohort, we identified patients tested for Covid-19 from date of first recorded VA test on
118 February 8, 2020 through March 30, 2020. Available data included demographics, outpatient
119 and inpatient encounters, diagnoses, laboratory results, vital signs, health factors (e.g., smoking
120 and alcohol health behaviors), and pharmacy dispensing records.

121

122 VA Birth Cohort was approved by the Institutional Review Boards of VA Connecticut Healthcare
123 System and Yale University. It has been granted a waiver of informed consent and is Health
124 Insurance Portability and Accountability Act compliant.

125

126 *Data Collection*

127 We selected previously validated cohort characteristics and those that have been evaluated in
128 prior Covid-19 reports.^{1,13} Baseline was defined as the date of specimen collection for the
129 Covid-19 test unless testing occurred during hospitalization, in which case it was date of
130 admission. Demographics included age at baseline, sex, race/ethnicity, and rural/urban
131 residence. Residence was defined using geographic information system coding based upon
132 established criteria.¹⁴

133

134 *Main Study Outcomes*

135 We examined three outcomes: 1) testing positive for SARS-CoV-2 (Covid-19+), 2)
136 hospitalization, and 3) admission to an intensive care unit (ICU). We used VA inpatient bed
137 section codes 12 (medical) and 13 (cardiac) to identify ICU admission.

138

139 *Covid-19 tests*

140 We identified Covid-19 tests conducted in the VA using text searching of laboratory results
141 containing terms consistent with SARS-CoV-2 or Covid-19. If a patient had more than one test
142 and all were negative we selected first negative, otherwise we used date of first positive.
143 Patients for whom results were pending (n=93) or inconclusive (n=33) were excluded. Nearly all
144 tests utilized nasopharyngeal swabs, 1% were from other sources. Testing was performed in VA,
145 state public health and commercial reference laboratories using emergency use authorization
146 approved SARS-CoV-2 assays.

147

148 *Comorbidity*

149 We extracted diagnostic codes for asthma, cancer, COPD, chronic kidney disease, diabetes
150 mellitus, hypertension, liver disease, vascular disease, and alcohol use disorder (definitions
151 provided in **eTable 1**). We used a validated algorithm to capture smoking status derived from
152 health factors.¹⁵

153

154 *Pharmacy Data*

155 We collected pharmacy fills for ACE/ARBs, chemotherapy and immunosuppressive drugs, and
156 prescription NSAIDs and determined which medications were active in the year prior to testing.
157 Exposure windows for NSAIDs ended 14 days prior to baseline to minimize the potential of
158 protopathic bias. Exposure windows for other medications not used to treat Covid-19
159 symptoms ended three days prior to baseline.

160

161 *Vital Signs, Clinical Laboratory Data, and a Summary Measure of Physiologic Injury*

162 Vital signs measured within two days of baseline included body mass index (BMI), oxygen
163 saturation, pulse, systolic blood pressure, and temperature. We chose laboratory findings
164 closest to baseline within a year prior or up to one week after baseline. Measures included
165 alanine aminotransferase, albumin, aspartate aminotransferase, creatinine, estimated
166 glomerular filtration rate,¹⁶ fibrosis-4 score (FIB-4),¹⁷ hemoglobin, platelet count, total white
167 blood cell count, and lymphocyte count. We calculated a validated composite measure of
168 physiologic injury (VACS Index) which includes age, BMI, and all previously mentioned
169 laboratory measures save lymphocyte count^{18,19} (details in **eMethods**).

170

171 *Statistical Analysis*

172 We evaluated characteristics of patients undergoing Covid-19 testing, and among Covid-19+,
173 factors associated with hospital admission and intensive care, using chi-square, Fisher's exact,
174 and Wilcoxon rank-sum tests, as appropriate. For bivariate comparisons, statistical significance
175 reflects complete case analysis. When modeling Covid-19+, we restricted analyses to factors
176 available when initially evaluating a patient (i.e., demographic data, comorbid conditions,

177 medication history, health behaviors, and vital signs). Because age, black race, ACE/ARB use,
178 and NSAID use are of special interest, we included them in all multivariable models. Otherwise,
179 variables significant at $p < 0.05$ in unadjusted analyses were included in the multivariable
180 models. When modeling hospital admission and intensive care, we compared C-statistics for
181 models including individual laboratory values to a model including VACS Index. In *post hoc*
182 analyses we explored the association between black race and Covid-19+ with a multivariable
183 model conditioned on site, among sites having at least five positive tests.

184
185 We report missing data for each variable. We used multiple imputation to impute missing
186 laboratory measures, vital signs, and smoking status. The imputation model included outcomes
187 and all covariates. Estimates from regressions performed on 10 imputed data sets were
188 combined using Rubin's rules.²⁰ Analyses were performed using SAS version 9.4 (SAS Institute
189 Inc., Cary, NC, USA) and Stata version 14.2 (StataCorp, LLC., College Station, TX). We used R
190 version 3.6.3 to map Covid-19 cases in the VA system overall and those captured in the VA Birth
191 Cohort.

192

193 **Results**

194 In the year prior to the Covid-19 outbreak, the VA Birth Cohort included 2,026,277 living
195 individuals: 1,866,256 (92.1%) men and 159,971 (7.9%) women. The cohort includes 1,369,454
196 (67.6%) white, 402,295 (19.9%) black, 106,639 (5.3%) Latinx, and 147,839 (7.3%) other or
197 unknown race/ethnicity. More than a third of the subjects (745,284 or 36.8%) were 70-75 years
198 of age, 23.3% (n=472,732) were 65-69 years old, 20.1% (n=407,900) were 60-64 years old, and

199 19.8% (n=400,311) were 54-59 years old. Of these, 3,789 individuals have been tested for
200 Covid-19 (18.7 per 10,000 persons) since February 8, 2020 through March 30, 2020.

201
202 Testing per 10,000 persons varied by race, sex, age, and residence ($p < 0.001$ for all). Black
203 Veterans were more likely to be tested than white Veterans (28.0 versus 15.6). Women were
204 more likely to be tested than men (23.3 versus 18.3). Testing generally decreased with age (age
205 54-59: 21.5; age 60-64: 22.2; age 65-69: 18.6; and age 70-75: 15.4). Veterans living in urban
206 settings were more likely to be tested than those in rural settings (39.2 vs. 5.8).

207
208 Among those tested, median age was 65.7 years (**Table 1**), 90.2% were male, 29.7% were black,
209 and 81.1% lived in urban settings. Common comorbid conditions were hypertension (65.0%),
210 diabetes mellitus (37.8%), vascular disease (28.9%), COPD (26.2%), and alcohol use disorder
211 (13.9%). Receipt of ACE/ARBs (40.5%) or NSAIDs (30.5%) was common. Among those tested,
212 42.3% were current smokers, 40.8% were obese (BMI > 30 kg/m²), 7.7% were febrile ($\geq 100.4^\circ\text{F}$),
213 13.1% were hypoxic (oxygen saturation $\leq 93\%$), and 35.4% were tachycardic (pulse ≥ 90 beats
214 per minute).

215
216 *Testing Positive vs. Negative for Covid-19*

217 Of the 3,789 patients tested in the VA Birth Cohort, 585 (15.4%, 95% CI 14.3-16.6) were Covid-
218 19+, representing approximately half (585/1244, 47%) of all Covid-19+ patients in the VA as of
219 March 30, 2020 (**Figure 1a** and **eFigure 1**). In unadjusted analyses, factors associated with
220 Covid-19+ (**Table 1**) included male sex, black race, urban residence, chronic kidney disease,

221 diabetes, and hypertension (all $p < 0.003$). Smoking, COPD, and alcohol use disorder were
222 associated with a lower probability of a positive test (all $p < 0.001$). No medication exposure was
223 associated with a positive test. Vital signs associated with Covid-19+ included higher BMI,
224 tachycardia, and higher temperature (all $p < 0.001$). All laboratory values were associated with
225 Covid-19+ (all $p < 0.001$). Composite variables, eGFR and FIB-4, were also strongly associated
226 (both $p < 0.001$).

227
228 In multivariable analyses (**Table 2**, C-statistic=0.806), black race (OR 4.68, 95% CI 3.79-5.78),
229 male sex (OR 3.17, 95% CI 2.03-4.94), urban residence (OR 1.60, 95% CI 1.17-2.20), higher
230 temperature (OR 1.70, 95% CI 1.58-1.84 per 1°F), lower systolic blood pressure (OR 1.44, 95% CI
231 1.16-1.78), and prior use of NSAIDs (OR 1.27, 95% CI 1.02-1.58) were associated with increased
232 likelihood of Covid-19+. Current smoking (OR 0.45, 95% CI 0.35-0.57), alcohol use disorder (OR
233 0.58, 95% CI 0.41-0.83), and COPD (OR 0.67, 95% CI 0.50-0.88) were associated with decreased
234 likelihood of Covid-19+. Results were similar in complete case analysis (**eTable 2**).

235
236 In *post hoc* analyses, we observed that black Veterans were more likely to be tested at sites
237 with higher Covid-19 prevalence (**Figure 1b**). A model conditional on site (**Table 2**) reduced the
238 association with black race (OR 2.56, 95% CI 1.89-3.46) and increased the association with male
239 sex (OR 3.85, 95% CI 2.20-6.74). Associations with other factors were consistent with
240 unconditional estimates.

241

242 *Risk Factors for Hospitalization and Intensive Care*

243 Among 585 Covid-19+ patients, 297 (50.8%, 95% CI 46.6-54.9%) were hospitalized and 122
244 (20.9%, 95% CI 17.6-24.4%) received intensive care. In bivariate analyses, age, chronic kidney
245 disease, COPD, diabetes, hypertension, vascular disease, ACE/ARB exposure, and decreased
246 oxygen saturation, and elevated temperature were associated with hospitalization and
247 intensive care (all $p < 0.05$, **Table 3a and Table 3b**). All laboratory abnormalities investigated
248 were associated with hospitalization and intensive care (all $p < 0.05$). Median VACS Index scores
249 varied substantially between those hospitalized versus not hospitalized (78.7 vs. 66.2, $p < 0.001$)
250 and between those receiving and not receiving intensive care (82.0 vs. 69.4, $p < 0.001$).

251
252 Parallel models, first adjusted for all significant factors identified in bivariate analyses and then
253 substituting VACS Index for all laboratory tests, demonstrated good discrimination for
254 hospitalization (**Table 4**, C-statistics: 0.859, 0.834) and intensive care (C-statistics: 0.876, 0.835).
255 White blood cell count, lymphocyte count, eGFR, albumin and FIB-4 were all independently
256 associated with hospitalization and intensive care (**Table 4**). The most pronounced association
257 was for patients with $FIB-4 > 3.25$ – adjusted OR 8.73 (95% CI 4.11-18.56) for hospitalization and
258 8.40 (95% CI 2.90-24.28) for intensive care – compared to those with $FIB-4 < 1.45$. Of note,
259 associations were stronger for FIB-4 and eGFR than for components of these measures (data
260 not otherwise shown).

261
262 While COPD, diabetes, hypertension, kidney disease, vascular disease and exposure to ACE/ARB
263 exposure were associated with hospitalization and intensive care in unadjusted analyses, they

264 were not significantly associated after adjusting for laboratory abnormalities and vital signs
265 (**Table 4**). Results were similar in complete case analysis (**eTable 3**).

266

267 **Discussion**

268 Our analysis represents over 2 million veterans, aged 54-75 years, receiving care in the largest
269 integrated healthcare system in the United States. The study was conducted within an
270 established cohort and based on well annotated national electronic health record data,
271 enabling a rapid and reliable analysis of Covid-19 testing and initial outcomes. As a result, we
272 were able to validate and extend previous findings, to include a careful consideration of who is
273 Covid-19+ and, given a positive test, what factors were independently associated with
274 hospitalization and intensive care. We found that black Veterans were twice as likely to be
275 tested and 2.5 times as likely to test positive than non-black Veterans, even after adjusting for
276 urban residence and conditioning on geographic location. While we saw modest evidence of an
277 association between exposure to NSAIDs and risk of Covid-19+, vital signs and laboratory
278 measures better characterized risk of hospitalization and intensive care than did comorbid
279 diagnoses or prior medication exposures.

280

281 In unadjusted analyses, black Veterans were over four times as likely to test positive compared
282 to non-black Veterans; adjusting for urban versus rural residence did not change this
283 association. While black Veterans were much more likely to be tested at high prevalence
284 facilities, conditioning our analysis by site did not eliminate the association; black race retained
285 over a two-fold increased risk for testing Covid-19+. Of note, black Veterans were also more

286 likely to be tested, which could dilute the proportion positive. Further, black Veterans did not
287 experience higher rates of hospitalization or intensive care. Based on prior experience with
288 1918 Spanish Flu and 2009 H1N1 epidemic, public health experts have warned that minority
289 populations may be at higher risk of infection due to reduced capacity to implement physical
290 distancing.^{21,22} Our findings may be an underestimate of the US population as racial health
291 disparities in VA tend to be smaller than in the private sector.²³

292

293 Women were more likely to be tested for Covid-19 than men, and men were twice as likely to
294 test positive. This association strengthened after adjustment and in conditional analyses (**Table**
295 **2**) but should be considered preliminary given limited numbers of women in this analysis.

296

297 As reported previously²⁴ elevated temperature was independently associated with testing
298 positive, hospital admission and intensive care, underscoring the value of including fever in the
299 current testing algorithms. Findings from the multivariable regression suggest that other factors
300 might also be used to indicate a test, including black race, male sex, and lack of an alternative
301 explanation for cough symptoms. To wit, we found that current smoking, COPD, and alcohol
302 use disorder, factors that generally increase risk of pneumonia, were associated with decreased
303 probability of testing positive. While they were not associated with hospitalization or intensive
304 care, it is too early to tell if these factors are associated with subsequent outcomes such as
305 respiratory failure or mortality.

306

307 Presence of particular comorbid diagnoses may be less prognostic than overall acute on chronic
308 injury reflected in laboratory abnormalities largely encompassed in the VACS Index. In
309 unadjusted analyses, several comorbid conditions were associated with hospitalization and
310 intensive care but were not independently associated after adjusting for vital signs and
311 laboratory data. Further, while elevated white blood cell counts and decreased lymphocyte
312 counts were associated with hospitalization and intensive care, the pronounced independent
313 association with FIB-4 (a composite of platelets and transaminases) and albumin suggest that
314 virally induced hepatic inflammation may be a harbinger of the cytokine storm.²⁵⁻²⁷

315
316 VACS Index, which includes FIB-4, albumin, and white blood cell count, is predictive of mortality
317 in many clinical settings.¹⁸ A five-point difference in score corresponds to a 30% difference in
318 mortality. The 12.5-point difference in medians between the Veterans who were and were not
319 admitted, and the 12.6-point difference between those who received and did not receive
320 intensive care underscores the wide range of prognoses seen with Covid-19. Future work will
321 need to determine whether VACS Index might be used in medical triage of Covid-19+ patients.

322
323 Our analysis is one of the first to address concerns regarding exposure to NSAIDs and ACE/ARBs
324 and Covid-19.^{9,10} We found NSAID exposure was modestly associated with Covid-19+ in
325 unadjusted and adjusted analyses, but not with hospitalization or intensive care. Among those
326 testing positive, ACE/ARB exposure was associated with hospitalization and intensive care in
327 unadjusted analyses, but associations lost statistical significance with hospitalization and
328 diminished with intensive care after adjusting for clinical measures, including hypertension and

329 blood pressure. However, confidence intervals were wide, include clinically important
330 differences, and conclusions may change as the epidemic evolves. We will continue to update
331 these analyses as more data become available.

332
333 While this analysis adds information to the evolving pandemic, its limitations must be kept in
334 mind. First, a small proportion of Veterans have been tested and rates of testing vary widely by
335 site. Second, women represented a small number of Veterans in the sample (184 tested, 13
336 positive). Third, our analysis of outcomes is preliminary as many Covid-19+ patients are still in
337 care. Fourth, while a strength of this analysis is our ability to determine active VA medications,
338 we could only detect NSAID exposure based upon VA pharmacy fill/refill data, individuals are
339 also likely to purchase NSAIDS over the counter. As real-world data become available, more
340 sophisticated and focused pharmacoepidemiological analyses will be required to address
341 concerns regarding potential risk of medications associated with Covid-19.

342
343 **Conclusion**

344 Black race was strongly associated with Covid-19+, but not with hospitalization or intensive
345 care. Unadjusted associations between medication exposure, comorbid disease, and
346 hospitalization and intensive care are diminished after adjustment. Risk of hospitalization and
347 intensive care associated with Covid-19 may be better characterized by vital signs and
348 measures of physiologic injury than by comorbid conditions or medication history.

349 **Acknowledgements**

350 The views and opinions expressed in this manuscript are those of the authors and do not
351 necessarily represent those of the Department of Veterans Affairs or the United States
352 Government. The authors wish to recognize Dr. Kendall Bryant as the NIAAA Scientific
353 Collaborator for the Veterans Birth Cohort. The authors thank Dr. Jennifer Thompson for her
354 feedback regarding helpful data presentation and important characteristics to include to enable
355 statistical modeling of the Covid-19 pandemic.

356 **References**

- 357 1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China.
358 *The New England journal of medicine*. 2020.
- 359 2. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet*.
360 2020.
- 361 3. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan
362 coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Infect Dis*.
363 2020.
- 364 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
365 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020.
- 366 5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
367 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From
368 the Chinese Center for Disease Control and Prevention. *JAMA*. 2020.
- 369 6. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591
370 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
371 *JAMA*. 2020.
- 372 7. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions
373 Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28,
374 2020. *MMWR Morb Mortal Wkly Rep*.
375 doi:<http://dx.doi.org/10.15585/mmwr.mm6913e2>. Published 31 March 2020. Accessed
376 31 March 2020.

- 377 8. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the
378 Seattle Region - Case Series. *The New England journal of medicine*. 2020.
- 379 9. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors
380 and scientists. *BMJ*. 2020;368:m1086.
- 381 10. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at
382 increased risk for COVID-19 infection? *Lancet Respir Med*. 2020.
- 383 11. Njei B, Esserman D, Krishnan S, et al. Regional and Rural-Urban Differences in the Use of
384 Direct-acting Antiviral Agents for Hepatitis C Virus: The Veteran Birth Cohort. *Med Care*.
385 2019;57(4):279-285.
- 386 12. Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in
387 hepatitis C testing in U.S. veterans born 1945-1965. *J Hepatol*. 2016;65(2):259-265.
- 388 13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
389 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*.
390 2020;395(10229):1054-1062.
- 391 14. Abrams TE, Vaughan-Sarrazin M, Kaboli PJ. Mortality and revascularization following
392 admission for acute myocardial infarction: implication for rural veterans. *J Rural Health*.
393 2010;26(4):310-317.
- 394 15. McGinnis KA, Brandt CA, Skanderson M, et al. Validating smoking data from the
395 Veteran's Affairs Health Factors dataset, an electronic data source. *Nicotine Tob Res*.
396 2011;13(12):1233-1239.
- 397 16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration
398 rate. *Ann Intern Med*. 2009;150(9):604-612.

- 399 17. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to
400 predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*.
401 2006;43(6):1317-1325.
- 402 18. Justice AC, Tate JP. Strengths and Limitations of the Veterans Aging Cohort Study Index
403 as a Measure of Physiologic Frailty. *AIDS Res Hum Retroviruses*. 2019;35(11-12):1023-
404 1033.
- 405 19. Tate JP, Sterne JAC, Justice AC, Veterans Aging Cohort S, the Antiretroviral Therapy
406 Cohort C. Albumin, white blood cell count, and body mass index improve discrimination
407 of mortality in HIV-positive individuals. *AIDS*. 2019;33(5):903-912.
- 408 20. Rubin DB. *Multiple Imputation for nonresponse in surveys*. Vol 81: John Wiley & Sons;
409 2004.
- 410 21. Centers for Disease Control and Prevention. Flu-Related Hospitalizations and Deaths in
411 the United States from April 2009 – January 30, 2010.
412 https://www.cdc.gov/H1N1flu/hosp_deaths_ahdra.htm. Published 2010. Accessed April
413 2, 2020.
- 414 22. Hutchins SS, Fiscella K, Levine RS, Ompad DC, McDonald M. Protection of racial/ethnic
415 minority populations during an influenza pandemic. *Am J Public Health*. 2009;99 Suppl
416 2:S261-270.
- 417 23. Peterson K, Anderson J, Boundy E, Ferguson L, McCleery E, Waldrip K. Mortality
418 Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An
419 Evidence Review and Map. *Am J Public Health*. 2018;108(3):e1-e11.

- 420 24. Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global
421 emergency: A review of the 2019 novel coronavirus (COVID-19). *Int J Surg.* 2020;76:71-
422 76.
- 423 25. Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. *Nat Rev*
424 *Gastroenterol Hepatol.* 2016;13(2):88-110.
- 425 26. Racanelli V, Rehermann B. The liver as an immunological organ. *Hepatology.* 2006;43(2
426 Suppl 1):S54-62.
- 427 27. Ramadori G, Armbrust T. Cytokines in the liver. *Eur J Gastroenterol Hepatol.*
428 2001;13(7):777-784.
- 429
430

431 **Figure legends**

432 **Figure 1.** Distribution of Covid-19 cases in the Veterans Birth Cohort as of March 30, 2020

433 **Caption:** (a) Shown is the distribution of 585/1244 (47%) Covid-19 cases in the Veterans Health

434 Administration captured in the Veterans Birth Cohort as of March 30, 2020 and included in the

435 current study. (b) Shown is the proportion of Covid-19 test results that are positive by the

436 proportion of Covid-19 cases of black race by site of care.

437

Table 1. Characteristics of patients tested for Covid-19 among all patients aged 54-75 years in the Veterans Health Administration as of March 30, 2020

			Covid-19 test result				p-value ^a	% Covid-19+ (95% CI)
	No. tested	(%)	missing	Positive	(%)	Negative		
Sample size, n	3789	(100.0)		585	(100.0)	3204	(100.0)	15.4 (14.3-16.6)
Demographics								
Age, years								
Median (IQR)	65.7 (60.5-70.7)		0	66.1 (60.4-71.0)		65.6 (60.5-70.7)		0.24
54-59	861 (22.7)			135 (23.1)		726 (22.7)		0.21
60-64	906 (23.9)			135 (23.1)		771 (24.1)		
65-69	877 (23.1)			120 (20.5)		757 (23.6)		
70-75	1145 (30.2)			195 (33.3)		950 (29.7)		
Sex								
Female	372 (9.8)		0	27 (4.6)		345 (10.8)		<0.001
Male	3417 (90.2)			558 (95.4)		2859 (89.2)		
Race/ethnicity								
White	2135 (56.3)		0	161 (27.5)		1974 (61.6)		<0.001
Black	1126 (29.7)			350 (59.8)		776 (24.2)		
Latinx	294 (7.8)			48 (8.2)		246 (7.7)		
Other/unknown	234 (6.2)			26 (4.4)		208 (6.5)		
Residence type								
Rural	718 (18.9)		0	56 (9.6)		662 (20.7)		<0.001
Urban	3071 (81.1)			529 (90.4)		2542 (79.3)		
Baseline comorbidity								
Asthma								
No	3506 (92.5)		0	540 (92.3)		2966 (92.6)		0.80
Yes	283 (7.5)			45 (7.7)		238 (7.4)		
Cancer								
No	3218 (84.9)		0	502 (85.8)		2716 (84.8)		0.57
Yes	571 (15.1)			83 (14.2)		488 (15.2)		
Chronic kidney disease								
No	3228 (85.2)		0	474 (81.0)		2754 (86.0)		0.003
Yes	561 (14.8)			111 (19.0)		450 (14.0)		
Chronic obstructive pulmonary disease								
No	2796 (73.8)		0	495 (84.6)		2301 (71.8)		<0.001
Yes	993 (26.2)			90 (15.4)		903 (28.2)		
Diabetes mellitus								
No	2358 (62.2)		0	325 (55.6)		2033 (63.5)		<0.001
Yes	1431 (37.8)			260 (44.4)		1171 (36.5)		
Hypertension								
No	1326 (35.0)		0	162 (27.7)		1164 (36.3)		<0.001
Yes	2463 (65.0)			423 (72.3)		2040 (63.7)		
Liver disease								
No	3323 (87.7)		0	525 (89.7)		2798 (87.3)		0.12
Yes	466 (12.3)			60 (10.3)		406 (12.7)		
Vascular disease								
No	2694 (71.1)		0	422 (72.1)		2272 (70.9)		0.59
Yes	1095 (28.9)			163 (27.9)		932 (29.1)		
Substance use								
Alcohol use disorder								
No	3261 (86.1)		0	537 (91.8)		2724 (85.0)		<0.001
Yes	528 (13.9)			48 (8.2)		480 (15.0)		
Smoking								
Never	1042 (27.5)		261	216 (36.9)		826 (25.8)		<0.001
Former	883 (23.3)			179 (30.6)		704 (22.0)		
Current	1603 (42.3)			159 (27.2)		1444 (45.1)		
Medication history in year prior to test date								
Any angiotensin converting enzyme inhibitor or angiotensin II receptor blocker								
No	2257 (59.6)		0	330 (56.4)		1927 (60.1)		0.10
Yes	1532 (40.4)			255 (43.6)		1277 (39.9)		
Angiotensin converting enzyme inhibitor								
No	2778 (73.3)		0	416 (71.1)		2362 (73.7)		0.20
Yes	1011 (26.7)			169 (28.9)		842 (26.3)		
Angiotensin II receptor blocker								
No	3226 (85.1)		0	491 (83.9)		2735 (85.4)		0.38
Yes	563 (14.9)			94 (16.1)		469 (14.6)		
Chemotherapy or immunosuppressive drug								
No	3568 (94.2)		0	556 (95.0)		3012 (94.0)		0.39
Yes	221 (5.8)			29 (5.0)		192 (6.0)		
Nonsteroidal anti-inflammatory drug, (-365, -14 days)								
No	2634 (69.5)		0	392 (67.0)		2242 (70.0)		0.16
Yes	1155 (30.5)			193 (33.0)		962 (30.0)		
Vital signs at test date								
Body mass index, kg/m ²								
<25.0	779 (20.6)		393	73 (12.5)		706 (22.0)		<0.001
25.0-29.9	1070 (28.2)			166 (28.4)		904 (28.2)		
≥30	1547 (40.8)			291 (49.7)		1256 (39.2)		
Hypoxia [oxygen saturation ≤93%]								

No	2433	(64.2)	860	443	(75.7)	1990	(62.1)	0.20	18.2	(16.7-19.8)
Yes	496	(13.1)		78	(13.3)	418	(13.0)		15.7	(12.6-19.2)
Pulse ≥90 beats per minute										
No	2033	(53.7)	416	295	(50.4)	1738	(54.2)	<0.001	14.5	(13.0-16.1)
Yes	1340	(35.4)		257	(43.9)	1083	(33.8)		19.2	(17.1-21.4)
Systolic blood pressure, mm Hg										
<90	355	(9.4)	448	63	(10.8)	292	(9.1)	0.11	17.8	(13.9-22.1)
90-140	1565	(41.3)		274	(46.8)	1291	(40.3)		17.5	(15.7-19.5)
≥140	1421	(37.5)		211	(36.1)	1210	(37.8)		14.9	(13.0-16.8)
Temperature, °F										
≤98.6	2142	(56.5)	405	204	(34.9)	1938	(60.5)	<0.001	9.5	(8.3-10.9)
98.7-100.3	953	(25.2)		227	(38.8)	726	(22.7)		23.8	(21.2-26.7)
≥100.4	289	(7.6)		120	(20.5)	169	(5.3)		41.5	(35.8-47.4)
La boratory findings at test date										
Alanine aminotransferase, U/L										
Median (IQR)	23.0	(16.0-34.0)	400	28.0	(19.0-41.0)	22.0	(16.0-33.0)	<0.001		
≤40	2829	(74.7)		406	(69.4)	2423	(75.6)	<0.001	14.4	(13.1-15.7)
>40	560	(14.8)		138	(23.6)	422	(13.2)		24.6	(21.1-28.4)
Albumin, g/dL										
Median (IQR)	3.9	(3.5-4.2)	383	3.8	(3.5-4.2)	3.9	(3.5-4.2)	0.78		
≥3.5	2596	(68.5)		415	(70.9)	2181	(68.1)	1.00	16.0	(14.6-17.5)
<3.5	810	(21.4)		129	(22.1)	681	(21.3)		15.9	(13.5-18.6)
Aspartate aminotransferase, U/L										
Median (IQR)	23.0	(18.0-32.0)	356	29.0	(21.5-43.0)	22.0	(17.0-30.0)	<0.001		
≤40	2902	(76.6)		391	(66.8)	2511	(78.4)	<0.001	13.5	(12.3-14.8)
>40	531	(14.0)		157	(26.8)	374	(11.7)		29.6	(25.7-33.7)
Creatinine, mg/dL										
Median (IQR)	1.1	(0.9-1.3)	186	1.1	(1.0-1.5)	1.0	(0.9-1.3)	<0.001		
≤1.5	3033	(80.0)		435	(74.4)	2598	(81.1)	<0.001	14.3	(13.1-15.6)
>1.5	570	(15.0)		130	(22.2)	440	(13.7)		22.8	(19.4-26.5)
eGFR, mL/min										
Median (IQR)	75.0	(59.0-91.0)	168	71.5	(53.0-87.0)	76.0	(60.0-92.0)	<0.001		
≥15	3492	(92.2)		541	(92.5)	2951	(92.1)	0.11	15.5	(14.3-16.7)
<15	129	(3.4)		27	(4.6)	102	(3.2)		20.9	(14.3-29.0)
FIB-4										
<1.45	1499	(39.6)	628	139	(23.8)	1360	(42.4)	<0.001	9.3	(7.9-10.9)
1.45-3.25	1266	(33.4)		263	(45.0)	1003	(31.3)		20.8	(18.6-23.1)
>3.25	396	(10.5)		114	(19.5)	282	(8.8)		28.8	(24.4-33.5)
Hemoglobin, g/dL										
Median (IQR)	13.8	(12.2-15.0)	445	13.9	(12.6-14.9)	13.8	(12.2-15.0)	0.09		
≥10	3097	(81.7)		523	(89.4)	2574	(80.3)	<0.001	16.9	(15.6-18.3)
<10	247	(6.5)		17	(2.9)	230	(7.2)		6.9	(4.1-10.8)
Platelet count, K/μL										
Median (IQR)	218	(173-267)	423	193	(154-230)	223	(178-275)	<0.001		
≥150	2875	(75.9)		416	(71.1)	2459	(76.7)	<0.001	14.5	(13.2-15.8)
<150	491	(13.0)		121	(20.7)	370	(11.5)		24.6	(20.9-28.7)
White blood cell count, K/μL										
Median (IQR)	7.5	(5.7-10.0)	288	5.9	(4.7-7.5)	7.8	(6.0-10.4)	<0.001		
<4	191	(5.0)		72	(12.3)	119	(3.7)	<0.001	37.7	(30.8-45.0)
4-9.9	2448	(64.6)		432	(73.8)	2016	(62.9)		17.7	(16.2-19.2)
≥10	862	(22.8)		49	(8.4)	813	(25.4)		5.7	(4.2-7.5)
Lymphocyte count, K/μL										
Median (IQR)	1.4	(1.0-2.0)	628	1.1	(0.8-1.6)	1.5	(1.0-2.1)	<0.001		
≥0.8	2626	(69.3)		363	(62.1)	2263	(70.6)	<0.001	13.8	(12.5-15.2)
<0.8	535	(14.1)		130	(22.2)	405	(12.6)		24.3	(20.7-28.2)
Clinical outcomes										
Hospitalized										
No	2277	(60.1)	0	288	(49.2)	1989	(62.1)	<0.001	12.7	(11.3-14.1)
Yes	1512	(39.9)		297	(50.8)	1215	(37.9)		19.6	(17.7-21.7)
Intensive care unit admission										
No	3381	(89.2)	0	463	(79.1)	2918	(91.1)	<0.001	13.7	(12.6-14.9)
Yes	408	(10.8)		122	(20.9)	286	(8.9)		29.9	(25.5-34.6)
Death during hospitalization										
No	3744	(98.8)	0	568	(97.1)	3176	(99.1)	<0.001	15.2	(14.0-16.4)
Yes	45	(1.2)		17	(2.9)	28	(0.9)		37.8	(23.8-53.5)

Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis 4 score

*P-values calculated on non-missing data

438

439

440

441

Table 2. Crude and adjusted associations with testing positive for Covid-19 as of March 30, 2020

	Positive Covid-19 test (n=585/3789)		
	Univariable OR (95% CI)	Multivariable OR (95% CI)	Conditional OR ^a (95% CI)
Model details			
C-statistic	-	0.806	n/a
Demographics			
Age, per 5-year increase	1.04 (0.97-1.12)	1.05 (0.96-1.15)	1.02 (0.91-1.15)
Sex, male vs. female	2.49 (1.67-3.73)	3.17 (2.03-4.94)	3.85 (2.20-6.74)
Race/ethnicity, black vs. other	4.66 (3.88-5.60)	4.68 (3.79-5.78)	2.56 (1.89-3.46)
Residence type, urban vs. rural	2.46 (1.84-3.28)	1.60 (1.17-2.20)	1.04 (0.64-1.68)
Baseline comorbidity			
Chronic kidney disease, yes vs. no	1.43 (1.14-1.80)	1.00 (0.76-1.33)	0.92 (0.64-1.31)
Chronic obstructive pulmonary disease, yes vs. no	0.46 (0.37-0.59)	0.67 (0.50-0.88)	0.77 (0.54-1.09)
Diabetes mellitus, yes vs. no	1.39 (1.16-1.66)	1.01 (0.80-1.26)	0.89 (0.67-1.19)
Hypertension, yes vs. no	1.49 (1.23-1.81)	1.23 (0.95-1.60)	1.40 (1.00-1.96)
Substance use			
Alcohol use disorder, yes vs. no	0.51 (0.37-0.69)	0.58 (0.41-0.83)	0.52 (0.34-0.82)
Current smoking, yes vs. no	0.43 (0.35-0.52)	0.45 (0.35-0.57)	0.45 (0.34-0.61)
Medication history in year prior to test date			
Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, yes vs. no	1.17 (0.98-1.39)	0.98 (0.78-1.23)	0.93 (0.69-1.24)
Nonsteroidal anti-inflammatory drug, yes vs. no	1.15 (0.95-1.39)	1.27 (1.02-1.58)	1.16 (0.87-1.54)
Vital signs			
Systolic blood pressure, <140 vs. ≥140 mm Hg	1.25 (1.03-1.51)	1.44 (1.16-1.78)	1.29 (0.99-1.69)
Body mass index, per 5 kg/m ² increase	1.15 (1.08-1.23)	1.09 (1.00-1.18)	1.10 (0.99-1.22)
Oxygen saturation, ≤93% vs >93%	0.88 (0.68-1.15)	1.04 (0.76-1.42)	1.04 (0.67-1.61)
Pulse, per 5-beats per minute increase	0.99 (0.99-1.00)	0.99 (0.99-1.00)	1.00 (0.99-1.00)
Temperature, per 1°F increase	1.74 (1.62-1.87)	1.70 (1.58-1.84)	1.69 (1.53-1.88)

Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval

^aModeling stations with five or more Covid-19 cases and conditioning on station

442

443

444

445

Table 3a. Associations with hospitalization among Covid-19 cases aged 54-75 years in the Veterans Health Administration as of March 30, 2020

	No. cases	(%)	missing	Hospitalization					
				Yes	(%)	No	(%)	p-value ^a	% hospitalized (95% CI)
n	585	(100)		297	(100.0)	288	(100.0)		50.8 (46.6-54.9)
Demographics									
Age, years									
Median (IQR)	66.1 (60.4-71.0)		0	67.6 (61.7-71.6)		64.5 (59.7-70.5)		0.001	
54-59	135 (23.1)			58 (19.5)		77 (26.7)		0.02	43.0 (34.5-51.8)
60-64	135 (23.1)			62 (20.9)		73 (25.3)			45.9 (37.3-54.7)
65-69	120 (20.5)			62 (20.9)		58 (20.1)			51.7 (42.4-60.9)
70-75	195 (33.3)			115 (38.7)		80 (27.8)			59.0 (51.7-66.0)
Sex									
Female	27 (4.6)		0	8 (2.7)		19 (6.6)		0.03	29.6 (13.8-50.2)
Male	558 (95.4)			289 (97.3)		269 (93.4)			51.8 (47.6-56.0)
Race/ethnicity									
White	161 (27.5)		0	79 (26.6)		82 (28.5)		0.32	49.1 (41.1-57.1)
Black	350 (59.8)			187 (63.0)		163 (56.6)			53.4 (48.1-58.8)
Latinx	48 (8.2)			20 (6.7)		28 (9.7)			41.7 (27.6-56.8)
Other/unknown	26 (4.4)			11 (3.7)		15 (5.2)			42.3 (23.4-63.1)
Residence type									
Rural	56 (9.6)		0	27 (9.1)		29 (10.1)		0.78	48.2 (34.7-62.0)
Urban	529 (90.4)			270 (90.9)		259 (89.9)			51.0 (46.7-55.4)
Baseline comorbidity									
Asthma									
No	540 (92.3)		0	273 (91.9)		267 (92.7)		0.76	50.6 (46.3-54.9)
Yes	45 (7.7)			24 (8.1)		21 (7.3)			53.3 (37.9-68.3)
Cancer									
No	502 (85.8)		0	252 (84.8)		250 (86.8)		0.55	50.2 (45.7-54.7)
Yes	83 (14.2)			45 (15.2)		38 (13.2)			54.2 (42.9-65.2)
Chronic kidney disease									
No	474 (81.0)		0	222 (74.7)		252 (87.5)		<0.001	46.8 (42.3-51.4)
Yes	111 (19.0)			75 (25.3)		36 (12.5)			67.6 (58.0-76.2)
Chronic obstructive pulmonary disease									
No	495 (84.6)		0	236 (79.5)		259 (89.9)		<0.001	47.7 (43.2-52.2)
Yes	90 (15.4)			61 (20.5)		29 (10.1)			67.8 (57.1-77.3)
Diabetes mellitus									
No	325 (55.6)		0	141 (47.5)		184 (63.9)		<0.001	43.4 (37.9-49.0)
Yes	260 (44.4)			156 (52.5)		104 (36.1)			60.0 (53.8-66.0)
Hypertension									
No	162 (27.7)		0	59 (19.9)		103 (35.8)		<0.001	36.4 (29.0-44.3)
Yes	423 (72.3)			238 (80.1)		185 (64.2)			56.3 (51.4-61.1)
Liver disease									
No	525 (89.7)		0	260 (87.5)		265 (92.0)		0.08	49.5 (45.2-53.9)
Yes	60 (10.3)			37 (12.5)		23 (8.0)			61.7 (48.2-73.9)
Vascular disease									
No	422 (72.1)		0	184 (62.0)		238 (82.6)		<0.001	43.6 (38.8-48.5)
Yes	163 (27.9)			113 (38.0)		50 (17.4)			69.3 (61.6-76.3)
Substance use									
Alcohol use disorder									
No	537 (91.8)		0	269 (90.6)		268 (93.1)		0.29	50.1 (45.8-54.4)
Yes	48 (8.2)			28 (9.4)		20 (6.9)			58.3 (43.2-72.4)
Smoking									
Never	216 (36.9)		31	106 (35.7)		110 (38.2)		0.30	49.1 (42.2-55.9)
Former	179 (30.6)			89 (30.0)		90 (31.3)			49.7 (42.2-57.3)
Current	159 (27.2)			90 (30.3)		69 (24.0)			56.6 (48.5-64.4)
Medication history in year prior to test date									
Any angiotensin converting enzyme inhibitor or angiotensin II receptor blocker									
No	330 (56.4)		0	150 (50.5)		180 (62.5)		0.004	45.5 (40.0-51.0)
Yes	255 (43.6)			147 (49.5)		108 (37.5)			57.7 (51.3-63.8)
Angiotensin converting enzyme inhibitor									
No	416 (71.1)		0	194 (65.3)		222 (77.1)		0.002	46.6 (41.8-51.6)
Yes	169 (28.9)			103 (34.7)		66 (22.9)			61.0 (53.2-68.4)
Angiotensin II receptor blocker									
No	491 (83.9)		0	248 (83.5)		243 (84.4)		0.82	50.5 (46.0-55.0)
Yes	94 (16.1)			49 (16.5)		45 (15.6)			52.1 (41.6-62.5)
Chemotherapy or immunosuppressive drug									
No	556 (95.0)		0	279 (93.9)		277 (96.2)		0.25	50.2 (45.9-54.4)
Yes	29 (5.0)			18 (6.1)		11 (3.8)			62.1 (42.3-79.3)
Nonsteroidal anti-inflammatory drug, (-365, -14 days)									
No	392 (67.0)		0	207 (69.7)		185 (64.2)		0.19	52.8 (47.7-57.8)
Yes	193 (33.0)			90 (30.3)		103 (35.8)			46.6 (39.4-53.9)
Vital signs at test date									
Body mass index, kg/m ²									
<25.0	73 (12.5)		55	45 (15.2)		28 (9.7)		0.25	61.6 (49.5-72.8)
25.0-29.9	166 (28.4)			85 (28.6)		81 (28.1)			51.2 (43.3-59.0)
≥30	291 (49.7)			149 (50.2)		142 (49.3)			51.2 (45.3-57.1)
Hypoxia (oxygen saturation ≤93%)									
No	443 (75.7)		64	226 (76.1)		217 (75.3)		<0.001	51.0 (46.3-55.8)

Yes	78 (13.3)		58 (19.5)	20 (6.9)		74.4 (63.2-83.6)
Pulse ≥90 beats per minute						
No	295 (50.4)	33	150 (50.5)	145 (50.3)	0.20	50.9 (45.0-56.7)
Yes	257 (43.9)		145 (48.8)	112 (38.9)		56.4 (50.1-62.6)
Systolic blood pressure, mm Hg						
<90	63 (10.8)	37	43 (14.5)	20 (6.9)	0.04	68.3 (55.3-79.4)
90-140	274 (46.8)		145 (48.8)	129 (44.8)		52.9 (46.8-59.0)
≥140	211 (36.1)		106 (35.7)	105 (36.5)		50.2 (43.3-57.2)
Temperature, °F						
≤98.6	204 (34.9)	34	88 (29.6)	116 (40.3)	0.002	43.1 (36.2-50.2)
98.7-100.3	227 (38.8)		134 (45.1)	93 (32.3)		59.0 (52.3-65.5)
≥100.4	120 (20.5)		70 (23.6)	50 (17.4)		58.3 (49.0-67.3)
Laboratory findings at test date						
Alanine aminotransferase, U/L						
Median (IQR)	28.0 (19.0-41.0)	41	30.0 (20.0-42.0)	26.0 (18.0-37.0)	0.01	
≤40	406 (69.4)		205 (69.0)	201 (69.8)	0.01	50.5 (45.5-55.5)
>40	138 (23.6)		87 (29.3)	51 (17.7)		63.0 (54.4-71.1)
Albumin, g/dL						
Median (IQR)	3.8 (3.5-4.2)	41	3.7 (3.3-4.0)	4.1 (3.7-4.3)	<0.001	
≥3.5	415 (70.9)		191 (64.3)	224 (77.8)	<0.001	46.0 (41.2-51.0)
<3.5	129 (22.1)		103 (34.7)	26 (9.0)		79.8 (71.9-86.4)
Aspartate aminotransferase, U/L						
Median (IQR)	29.0 (21.5-43.0)	37	35.5 (25.0-54.0)	25.0 (20.0-33.0)	<0.001	
≤40	391 (66.8)		173 (58.2)	218 (75.7)	<0.001	44.3 (39.3-49.3)
>40	157 (26.8)		121 (40.7)	36 (12.5)		77.1 (69.7-83.4)
Creatinine, mg/dL						
Median (IQR)	1.1 (1.0-1.5)	20	1.3 (1.0-1.8)	1.1 (0.9-1.3)	<0.001	
≤1.5	435 (74.4)		200 (67.3)	235 (81.6)	<0.001	46.0 (41.2-50.8)
>1.5	130 (22.2)		97 (32.7)	33 (11.5)		74.6 (66.2-81.8)
eGFR, mL/min						
Median (IQR)	71.5 (53.0-87.0)	17	63.0 (42.0-82.0)	75.0 (64.0-93.0)	<0.001	
≥15	541 (92.5)		277 (93.3)	264 (91.7)	0.03	51.2 (46.9-55.5)
<15	27 (4.6)		20 (6.7)	7 (2.4)		74.1 (53.7-88.9)
FIB-4						
<1.45	139 (23.8)	69	36 (12.1)	103 (35.8)	<0.001	25.9 (18.9-34.0)
1.45-3.25	263 (45.0)		153 (51.5)	110 (38.2)		58.2 (52.0-64.2)
>3.25	114 (19.5)		94 (31.6)	20 (6.9)		82.5 (74.2-88.9)
Hemoglobin, g/dL						
Median (IQR)	13.9 (12.6-14.9)	45	13.6 (12.0-14.7)	14.2 (13.2-15.1)	<0.001	
≥10	523 (89.4)		273 (91.9)	250 (86.8)	0.02	52.2 (47.8-56.6)
<10	17 (2.9)		14 (4.7)	3 (1.0)		82.4 (56.6-96.2)
Platelet count, K/μL						
Median (IQR)	193 (154-230)	48	175 (143-216)	208 (173-252)	<0.001	
≥150	416 (71.1)		200 (67.3)	216 (75.0)	<0.001	48.1 (43.2-53.0)
<150	121 (20.7)		88 (29.6)	33 (11.5)		72.7 (63.9-80.4)
White blood cell count, K/μL						
Median (IQR)	5.9 (4.7-7.5)	32	5.9 (4.6-7.7)	5.9 (4.7-7.3)	0.54	
<4	72 (12.3)		42 (14.1)	30 (10.4)	0.005	58.3 (46.1-69.9)
4-9.9	432 (73.8)		217 (73.1)	215 (74.7)		50.2 (45.4-55.1)
≥10	49 (8.4)		36 (12.1)	13 (4.5)		73.5 (58.9-85.1)
Lymphocyte count, K/μL						
Median (IQR)	1.1 (0.8-1.6)	92	0.9 (0.6-1.3)	1.4 (1.0-1.9)	<0.001	
≥0.8	363 (62.1)		179 (60.3)	184 (63.9)	<0.001	49.3 (44.1-54.6)
<0.8	130 (22.2)		105 (35.4)	25 (8.7)		80.8 (72.9-87.2)
VACS Index score ^b , median (IQR)	72.4 (63.6-82.5)	51	78.7 (71.1-87.3)	66.2 (60.0-73.2)	<0.001	

Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study

^aP-values calculated on non-missing data

^bThe VACS Index score is a validated measure of physiologic injury and combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index

446

447

448

449

450

451

Table 3b. Associations with intensive care among Covid-19 cases aged 54-75 years in the Veterans Health Administration as of March 30, 2020

	n				Intensive care					
		No. cases	(%)	missing	Yes	(%)	No	(%)	p-value ^a	% admitted (95% CI)
	585	(100)		122	(100.0)	463	(100.0)			20.9 (17.6-24.4)
Demographics										
Age, years										
Median (IQR)	66.1	(60.4-71.0)	0	69.9	(64.4-71.7)	64.7	(59.8-70.8)	<0.001		
54-59	135	(23.1)		11	(9.0)	124	(26.8)	<0.001		8.2 (4.1-14.1)
60-64	135	(23.1)		24	(19.7)	111	(24.0)			17.8 (11.7-25.3)
65-69	120	(20.5)		28	(23.0)	92	(19.9)			23.3 (16.1-31.9)
70-75	195	(33.3)		59	(48.4)	136	(29.4)			30.3 (23.9-37.2)
Sex										
Female	27	(4.6)	0	3	(2.5)	24	(5.2)	0.33		11.1 (2.4-29.2)
Male	558	(95.4)		119	(97.5)	439	(94.8)			21.3 (18.0-25.0)
Race/ethnicity										
White	161	(27.5)	0	37	(30.3)	124	(26.8)	0.89		23.0 (16.7-30.3)
Black	350	(59.8)		71	(58.2)	279	(60.3)			20.3 (16.2-24.9)
Latinx	48	(8.2)		9	(7.4)	39	(8.4)			18.8 (9.0-32.6)
Other/unknown	26	(4.4)		5	(4.1)	21	(4.5)			19.2 (6.6-39.4)
Residence type										
Rural	56	(9.6)	0	9	(7.4)	47	(10.2)	0.49		16.1 (7.6-28.3)
Urban	529	(90.4)		113	(92.6)	416	(89.8)			21.4 (17.9-25.1)
Baseline comorbidity										
Asthma										
No	540	(92.3)	0	111	(91.0)	429	(92.7)	0.57		20.6 (17.2-24.2)
Yes	45	(7.7)		11	(9.0)	34	(7.3)			24.4 (12.9-39.5)
Cancer										
No	502	(85.8)	0	104	(85.2)	398	(86.0)	0.88		20.7 (17.3-24.5)
Yes	83	(14.2)		18	(14.8)	65	(14.0)			21.7 (13.4-32.1)
Chronic kidney disease										
No	474	(81.0)	0	90	(73.8)	384	(82.9)	0.03		19.0 (15.6-22.8)
Yes	111	(19.0)		32	(26.2)	79	(17.1)			28.8 (20.6-38.2)
Chronic obstructive pulmonary disease										
No	495	(84.6)	0	94	(77.0)	401	(86.6)	0.02		19.0 (15.6-22.7)
Yes	90	(15.4)		28	(23.0)	62	(13.4)			31.1 (21.8-41.7)
Diabetes mellitus										
No	325	(55.6)	0	49	(40.2)	276	(59.6)	<0.001		15.1 (11.4-19.4)
Yes	260	(44.4)		73	(59.8)	187	(40.4)			28.1 (22.7-34.0)
Hypertension										
No	162	(27.7)	0	17	(13.9)	145	(31.3)	<0.001		10.5 (6.2-16.3)
Yes	423	(72.3)		105	(86.1)	318	(68.7)			24.8 (20.8-29.2)
Liver disease										
No	525	(89.7)	0	107	(87.7)	418	(90.3)	0.40		20.4 (17.0-24.1)
Yes	60	(10.3)		15	(12.3)	45	(9.7)			25.0 (14.7-37.9)
Vascular disease										
No	422	(72.1)	0	74	(60.7)	348	(75.2)	0.002		17.5 (14.0-21.5)
Yes	163	(27.9)		48	(39.3)	115	(24.8)			29.5 (22.6-37.1)
Substance use										
Alcohol use disorder										
No	537	(91.8)	0	115	(94.3)	422	(91.1)	0.35		21.4 (18.0-25.1)
Yes	48	(8.2)		7	(5.7)	41	(8.9)			14.6 (6.1-27.8)
Smoking										
Never	216	(36.9)	31	43	(35.2)	173	(37.4)	0.60		19.9 (14.8-25.9)
Former	179	(30.6)		36	(29.5)	143	(30.9)			20.1 (14.5-26.7)
Current	159	(27.2)		38	(23.9)	121	(26.1)			23.9 (17.5-31.3)
Medication history in year prior to test date										
Any angiotensin converting enzyme inhibitor or angiotensin II receptor blocker										
No	330	(56.4)	0	53	(43.4)	277	(59.8)	0.001		16.1 (12.3-20.5)
Yes	255	(43.6)		69	(56.6)	186	(40.2)			27.1 (21.7-33.0)
Angiotensin converting enzyme inhibitor										
No	416	(71.1)	0	72	(59.0)	344	(74.3)	0.002		17.3 (13.8-21.3)
Yes	169	(28.9)		50	(41.0)	119	(25.7)			29.6 (22.8-37.1)
Angiotensin II receptor blocker										
No	491	(83.9)	0	99	(81.1)	392	(84.7)	0.34		20.2 (16.7-24.0)
Yes	94	(16.1)		23	(18.9)	71	(15.3)			24.5 (16.2-34.4)
Chemotherapy or immunosuppressive drug										
No	556	(95.0)	0	115	(94.3)	441	(95.2)	0.64		20.7 (17.4-24.3)
Yes	29	(5.0)		7	(5.7)	22	(4.8)			24.1 (10.3-43.5)
Nonsteroidal anti-inflammatory drug, (-365, -14 days)										
No	392	(67.0)	0	90	(73.8)	302	(65.2)	0.08		23.0 (18.9-27.5)
Yes	193	(33.0)		32	(26.2)	161	(34.8)			16.6 (11.6-22.6)
Vital signs at test date										
Body mass index, kg/m ²										
<25.0	73	(12.5)	55	19	(15.6)	54	(11.7)	0.18		26.0 (16.5-37.6)
25.0-29.9	166	(28.4)		28	(23.0)	138	(29.8)			16.9 (11.5-23.5)
≥30	291	(49.7)		67	(23.0)	224	(48.4)			23.0 (18.3-28.3)
Hypoxia (oxygen saturation ≤93%)										
No	443	(75.7)	64	87	(71.3)	356	(76.9)	<0.001		19.6 (16.0-23.7)

Yes	78 (13.3)		30 (24.6)	48 (10.4)		38.5 (27.7-50.2)
Pulse ≥90 beats per minute						
No	295 (50.4)	33	53 (43.4)	242 (52.3)	0.02	18.0 (13.8-22.8)
Yes	257 (43.9)		68 (55.7)	189 (40.8)		26.5 (21.2-32.3)
Systolic blood pressure, mm Hg						
<90	63 (10.8)	37	17 (13.9)	46 (9.9)	0.57	27.0 (16.6-39.7)
90-140	274 (46.8)		60 (49.2)	214 (46.2)		21.9 (17.2-27.3)
≥140	211 (36.1)		44 (36.1)	167 (36.1)		20.9 (15.6-27.0)
Temperature, °F						
≤98.6	204 (34.9)	34	28 (23.0)	176 (38.0)	0.002	13.7 (9.3-19.2)
98.7-100.3	227 (38.8)		56 (45.9)	171 (36.9)		24.7 (19.2-30.8)
≥100.4	120 (20.5)		34 (27.9)	86 (18.6)		28.3 (20.5-37.3)
Laboratory findings at test date						
Alanine aminotransferase, U/L						
Median (IQR)	28.0 (19.0-41.0)	41	32.0 (21.0-47.0)	27.0 (19.0-38.0)	0.02	
≤40	406 (69.4)		78 (63.9)	328 (70.8)	0.004	19.2 (15.5-23.4)
>40	138 (23.6)		43 (35.2)	95 (20.5)		31.2 (23.6-39.6)
Albumin, g/dL						
Median (IQR)	3.8 (3.5-4.2)	41	3.6 (3.2-3.9)	3.9 (3.6-4.2)	<0.001	
≥3.5	415 (70.9)		68 (55.7)	347 (74.9)	<0.001	16.4 (13.0-20.3)
<3.5	129 (22.1)		54 (44.3)	75 (16.2)		41.9 (33.2-50.9)
Aspartate aminotransferase, U/L						
Median (IQR)	29.0 (21.5-43.0)	37	42.0 (27.0-68.0)	27.0 (21.0-39.0)	<0.001	
≤40	391 (66.8)		59 (48.4)	332 (71.7)	<0.001	15.1 (11.7-19.0)
>40	157 (26.8)		63 (51.6)	94 (20.3)		40.1 (32.4-48.2)
Creatinine, mg/dL						
Median (IQR)	1.1 (1.0-1.5)	20	1.4 (1.1-2.0)	1.1 (0.9-1.4)	<0.001	
≤1.5	435 (74.4)		72 (59.0)	363 (78.4)	<0.001	16.6 (13.2-20.4)
>1.5	130 (22.2)		50 (41.0)	80 (17.3)		38.5 (30.1-47.4)
eGFR, mL/min						
Median (IQR)	71.5 (53.0-87.0)	17	55.5 (37.0-76.0)	74.0 (58.0-90.0)	<0.001	
≥15	541 (92.5)		110 (90.2)	431 (93.1)	0.006	20.3 (17.0-24.0)
<15	27 (4.6)		12 (9.8)	15 (3.2)		44.4 (25.5-64.7)
FIB-4						
<1.45	139 (23.8)	69	6 (4.9)	133 (28.7)	<0.001	4.3 (1.6-9.2)
1.45-3.25	263 (45.0)		66 (54.1)	197 (42.5)		25.1 (20.0-30.8)
>3.25	114 (19.5)		44 (36.1)	70 (15.1)		38.6 (29.6-48.2)
Hemoglobin, g/dL						
Median (IQR)	13.9 (12.6-14.9)	45	13.6 (11.9-14.7)	14.0 (12.8-15.0)	0.02	
≥10	523 (89.4)		109 (89.3)	414 (89.4)	0.02	20.8 (17.4-24.6)
<10	17 (2.9)		8 (6.6)	9 (1.9)		47.1 (23.0-72.2)
Platelet count, K/μL						
Median (IQR)	193 (154-230)	48	175 (144-228)	195 (157-231)	0.05	
≥150	416 (71.1)		82 (19.7)	334 (72.1)	0.03	19.7 (16.0-23.9)
<150	121 (20.7)		35 (28.9)	86 (18.6)		28.9 (21.1-37.9)
White blood cell count, K/μL						
Median (IQR)	5.9 (4.7-7.5)	32	6.2 (5.2-8.9)	5.7 (4.6-7.2)	<0.001	
<4	72 (12.3)		12 (16.7)	60 (13.0)	0.002	16.7 (8.9-27.3)
4-9.9	432 (73.8)		89 (20.6)	343 (74.1)		20.6 (16.9-24.7)
≥10	49 (8.4)		21 (42.9)	28 (6.0)		42.9 (28.8-57.8)
Lymphocyte count, K/μL						
Median (IQR)	1.1 (0.8-1.6)	92	0.8 (0.6-1.1)	1.2 (0.8-1.8)	<0.001	
≥0.8	363 (62.1)		71 (19.6)	292 (63.1)	<0.001	19.6 (15.6-24.0)
<0.8	130 (22.2)		48 (36.9)	82 (17.7)		36.9 (28.6-45.8)
VACS Index score ^b , median (IQR)	72.4 (63.6-82.5)	51	82.0 (74.0-91.1)	69.4 (61.1-79.1)	<0.001	

Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study

^aP-values calculated on non-missing data

^bThe VACS Index score is a validated measure of physiologic injury and combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index

452

453

454

455

456

457



Table 4. Crude and adjusted associations with hospitalization and intensive care among Covid-19 cases as of March 30, 2020

	Hospitalization (n=297/585)			Intensive care (n=122/585)		
	Univariable OR (95% CI)	Multivariable OR (95% CI)	Multivariable OR (95% CI)	Univariable OR (95% CI)	Multivariable OR (95% CI)	Multivariable OR (95% CI)
Model details						
C-statistic	-	0.859	0.834	-	0.876	0.835
Demographics						
Age, per 5-year increase	1.26 (1.10-1.44)	0.87 (0.71-1.05)	0.64 (0.51-0.80)	1.55 (1.30-1.86)	1.31 (1.03-1.66)	0.98 (0.76-1.26)
Race/ethnicity, black vs. other	1.30 (0.94-1.82)	0.96 (0.61-1.53)	1.14 (0.74-1.74)	0.92 (0.61-1.38)	0.94 (0.55-1.63)	0.98 (0.60-1.61)
Baseline comorbidity						
Chronic kidney disease, yes vs. no	2.36 (1.53-3.66)	0.80 (0.41-1.56)	0.84 (0.47-1.49)	1.73 (1.08-2.77)	0.50 (0.24-1.06)	0.65 (0.35-1.21)
Chronic obstructive pulmonary disease, yes vs. no	2.31 (1.43-3.72)	1.77 (0.92-3.41)	1.15 (0.62-2.12)	1.93 (1.17-3.18)	1.81 (0.92-3.58)	1.47 (0.79-2.73)
Diabetes mellitus, yes vs. no	1.96 (1.41-2.73)	1.59 (1.00-2.53)	1.36 (0.89-2.09)	2.20 (1.46-3.30)	1.69 (0.96-2.98)	1.41 (0.85-2.35)
Hypertension, yes vs. no	2.25 (1.55-3.26)	1.39 (0.78-2.46)	1.50 (0.88-2.54)	2.81 (1.63-4.88)	1.51 (0.70-3.28)	1.89 (0.93-3.87)
Vascular disease, yes vs. no	2.92 (1.99-4.29)	1.58 (0.93-2.69)	1.58 (0.96-2.60)	1.96 (1.29-2.99)	0.73 (0.40-1.33)	0.77 (0.44-1.34)
Medication history in year prior to test date						
Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, yes vs. no	1.63 (1.17-2.27)	1.15 (0.71-1.87)	1.24 (0.79-1.95)	1.94 (1.30-2.90)	1.66 (0.94-2.93)	1.69 (1.01-2.84)
Nonsteroidal anti-inflammatory drug, yes vs. no	0.78 (0.55-1.10)	1.18 (0.74-1.89)	1.09 (0.71-1.67)	0.67 (0.43-1.04)	1.16 (0.65-2.06)	0.98 (0.57-1.67)
Vital signs						
Systolic blood pressure, per 5 mm Hg decrease	1.10 (1.03-1.17)	1.08 (1.00-1.18)	1.09 (1.00-1.17)	1.05 (0.98-1.13)	1.00 (0.92-1.10)	1.00 (0.91-1.09)
Oxygen saturation, per 1% decrease	1.14 (1.06-1.23)	1.04 (0.95-1.14)	1.12 (1.02-1.22)	1.16 (1.09-1.24)	1.05 (0.97-1.14)	1.13 (1.05-1.21)
Pulse, per 5-beats per minute increase	0.97 (0.95-0.99)	0.97 (0.95-0.99)	0.97 (0.95-0.99)	0.99 (0.97-1.00)	1.00 (0.97-1.02)	0.99 (0.97-1.01)
Temperature, per 1°F increase	1.20 (1.07-1.36)	1.15 (0.98-1.34)	1.24 (1.08-1.44)	1.28 (1.12-1.47)	1.32 (1.10-1.58)	1.37 (1.16-1.61)
Laboratory findings						
Albumin, per 1 g/dL decrease	10.43 (5.70-19.08)	3.75 (1.91-7.35)	-	6.17 (3.62-10.52)	3.34 (1.70-6.54)	-
eGFR, per 10 mL/min decrease	1.29 (1.19-1.40)	1.18 (1.05-1.32)	-	1.31 (1.21-1.43)	1.29 (1.15-1.46)	-
FIB-4						
<1.45	ref	ref	-	ref	ref	-
1.45-3.25	3.92 (2.53-6.08)	2.96 (1.69-5.17)	-	6.31 (2.74-14.50)	4.59 (1.72-12.22)	-
>3.25	12.37 (6.73-22.72)	8.73 (4.11-18.56)	-	12.43 (5.24-29.50)	8.40 (2.90-24.28)	-
Hemoglobin, per 1 g/dL decrease	1.55 (1.32-1.83)	1.16 (0.93-1.43)	-	1.33 (1.14, 1.54)	1.00 (0.81-1.23)	-
White blood cell count, per 1 K/ μ L increase	1.05 (0.96-1.15)	1.24 (1.08-1.43)	-	1.22 (1.10-1.36)	1.49 (1.27-1.73)	-
Lymphocyte count, per 1 K/ μ L decrease	2.68 (2.00-3.60)	2.38 (1.68-3.39)	-	2.76 (1.87-4.09)	2.65 (1.68-4.18)	-
VACS Index score ^a , per 5-point increase	1.48 (1.36-1.61)	-	1.62 (1.43-1.84)	1.45 (1.33-1.58)	-	1.47 (1.31-1.65)

Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study

^aThe VACS Index score is a validated measure of physiologic injury combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index

Figure 1. Distribution of Covid-19 cases in the Veterans Birth Cohort as of March 30, 2020



(a) Shown is the distribution of 585/1244 (47%) Covid-19 cases in the Veterans Health Administration captured in the Veterans Birth Cohort as of March 30, 2020 and included in the current study. (b) Shown is the proportion of Covid-19 test results that are positive by the proportion of Covid-19 cases of black race by site of care.